Kodiak Sciences Unveils Promising Clinical Data on KSI-101 for Macular Edema at IOIS 2025 Congress

Reuters

26 Jun

Kodiak Sciences Unveils Promising Clinical Data on KSI-101 for Macular Edema at IOIS 2025 Congress

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing treatments for retinal diseases, announced the upcoming presentation of highlights regarding their investigational drug, KSI-101, at the 2025 Congress of the International Ocular Inflammation Society in Rio de Janeiro, Brazil. The presentation is scheduled for June 27, 2025, and will focus on KSI-101, a bispecific intravitreal biologic targeting IL-6 and VEGF, aimed at treating macular edema secondary to inflammation (MESI). Insights from clinical cases and an expert panel will be included. The presentation can be accessed on Kodiak's website under the "Events and Presentations" section.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF18833) on June 25, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2546512226"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2546512226\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2546512226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-26 04:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546512226","market":"nz","top_or_hot":-1,"title":"Kodiak Sciences Unveils Promising Clinical Data on KSI-101 for Macular Edema at IOIS 2025 Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kodiak Sciences Unveils Promising Clinical Data on KSI-101 for Macular Edema at IOIS 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> (Nasdaq: KOD), a biopharmaceutical company focused on developing treatments for retinal diseases, announced the upcoming presentation of highlights regarding their investigational drug, KSI-101, at the 2025 Congress of the International Ocular Inflammation Society in Rio de Janeiro, Brazil. The presentation is scheduled for June 27, 2025, and will focus on KSI-101, a bispecific intravitreal biologic targeting IL-6 and VEGF, aimed at treating macular edema secondary to inflammation (MESI). Insights from clinical cases and an expert panel will be included. The presentation can be accessed on Kodiak's website under the \"Events and Presentations\" section.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF18833) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kodiak Sciences Unveils Promising Clinical Data on KSI-101 for Macular Edema at IOIS 2025 Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKodiak Sciences Unveils Promising Clinical Data on KSI-101 for Macular Edema at IOIS 2025 Congress\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-26 04:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Kodiak Sciences Unveils Promising Clinical Data on KSI-101 for Macular Edema at IOIS 2025 Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/KOD\">Kodiak Sciences Inc.</a> (Nasdaq: KOD), a biopharmaceutical company focused on developing treatments for retinal diseases, announced the upcoming presentation of highlights regarding their investigational drug, KSI-101, at the 2025 Congress of the International Ocular Inflammation Society in Rio de Janeiro, Brazil. The presentation is scheduled for June 27, 2025, and will focus on KSI-101, a bispecific intravitreal biologic targeting IL-6 and VEGF, aimed at treating macular edema secondary to inflammation (MESI). Insights from clinical cases and an expert panel will be included. The presentation can be accessed on Kodiak's website under the \"Events and Presentations\" section.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF18833) on June 25, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL9RKcfT:1","article_id":"2546512226","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546512226","pubTimestamp":1750884375,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Kodiak Sciences Inc. , a biopharmaceutical company focused on developing treatments for retinal diseases, announced the upcoming presentation of highlights regarding their investigational drug, KSI-101, at the 2025 Congress of the International Ocular Inflammation Society in Rio de Janeiro, Brazil. The presentation is scheduled for June 27, 2025, and will focus on KSI-101, a bispecific intravitreal biologic targeting IL-6 and VEGF, aimed at treating macular edema secondary to inflammation . Insights from clinical cases and an expert panel will be included. The presentation can be accessed on Kodiak's website under the \"Events and Presentations\" section.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","KOD":"Kodiak Sciences Inc.","BK4139":"生物科技"},"translate_title":"Kodiak Sciences在IOIS 2025大会上公布了KSI-101治疗黄斑水肿的有希望的临床数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":0.9},"content_text":"Kodiak Sciences Unveils Promising Clinical Data on KSI-101 for Macular Edema at IOIS 2025 Congress\n    \n\nKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company focused on developing treatments for retinal diseases, announced the upcoming presentation of highlights regarding their investigational drug, KSI-101, at the 2025 Congress of the International Ocular Inflammation Society in Rio de Janeiro, Brazil. The presentation is scheduled for June 27, 2025, and will focus on KSI-101, a bispecific intravitreal biologic targeting IL-6 and VEGF, aimed at treating macular edema secondary to inflammation (MESI). Insights from clinical cases and an expert panel will be included. The presentation can be accessed on Kodiak's website under the \"Events and Presentations\" section.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kodiak Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF18833) on June 25, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}